Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Pierre Fenaux(Université Paris Cité), Aref Al‐Kali(Mayo Clinic in Arizona), Maria R. Baer(U-M Rogel Cancer Center), Mikkael A. Sekeres(Cleveland Clinic), Gail J. Roboz(Cornell University), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Bart L. Scott(Fred Hutch Cancer Center), Peter L. Greenberg, Uwe Platzbecker, David P. Steensma(Dana-Farber Cancer Institute), Suman Kambhampati(University of Kansas Medical Center), Karl-Anton Kreuzer(Centrum für Integrierte Onkologie), Lucy A. Godley(University of Chicago Medical Center), Ehab Atallah(Medical College of Wisconsin), Robert H. Collins(The University of Texas Southwestern Medical Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), François Wilhelm(Onconova Therapeutics (United States)), N. Azarnia(Onconova Therapeutics (United States)), Lewis R. Silverman(Icahn School of Medicine at Mount Sinai)
Cited by 171
Abstract
Related Papers
No related papers found
Powered by citation graph analysis